Literature DB >> 2650788

Chemoradiotherapy toxicity during bone marrow transplantation: time course and variation in pain and nausea.

M K Chapko1, K L Syrjala, L Schilter, C Cummings, K M Sullivan.   

Abstract

Chemoradiotherapy-induced toxicity following unmodified allogeneic marrow grafting was studied. Patients with hematologic malignancy (n = 157) received cyclophosphamide (120 mg/kg) followed by single or fractionated total body irradiation (TBI); aplastic anemia patients (n = 41) received only cyclophosphamide (200 mg/kg). Physicians rated mucositis, pain and nausea daily as (0) none, (1) mild, (2) moderate, (3) severe, (4) life threatening. Oral mucositis pain began several days prior to transplant, peaked during the second week after transplant, and declined thereafter. Patients with hematologic malignancies (maximum mean rating of 1.6, day 11) experienced more pain than aplastic anemia patients (maximum mean rating of 0.7, day 6). Nausea peaked before transplant and gradually declined. Nausea was higher (p less than 0.001) in patients with aplastic anemia (maximum mean rating of 1.3, day -2) than with hematologic malignancies (maximum mean rating of 0.9, day -6). There was no significant difference between single dose 1000 cGy and 6-day 1200 cGy irradiation. Recipients of 1575 cGy rather than 1200 cGy TBI had significantly (p less than 0.01) higher levels of pain (mean rating 1.25 and 0.82, respectively) and nausea (mean rating 1.27 and 0.72, respectively). Additional research is needed to determine the predictors, consequences and best methods of controlling these toxicities.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2650788

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  A computer-based system for controlling plasma opioid concentration according to patient need for analgesia.

Authors:  H F Hill; R C Jacobson; B A Coda; A M Mackie
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

Review 2.  Alimentary tract mucositis in cancer patients: impact of terminology and assessment on research and clinical practice.

Authors:  Douglas E Peterson; Dorothy M Keefe; Ronald D Hutchins; Mark M Schubert
Journal:  Support Care Cancer       Date:  2006-04-26       Impact factor: 3.603

3.  Drug use evaluation of opioid analgesics in pain management among patients with hematopoietic stem cell transplantation.

Authors:  Hyun Jin Oh; So Yeon Hong; Young Mi Jeong; Kyung Suk Choi; Eunsook Lee; Euni Lee; Yu Jung Kim; Soo-Mee Bang
Journal:  Blood Res       Date:  2020-09-30

4.  A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation.

Authors:  Mark M Schubert; Fernanda P Eduardo; Katherine A Guthrie; Jean-Claude Franquin; Rene-Jean J Bensadoun; Cesar A Migliorati; C Michele E Lloid; Carlos P Eduardo; Niccoli-Filho Walter; Marcia M Marques; Mohd Hamdi
Journal:  Support Care Cancer       Date:  2007-03-29       Impact factor: 3.603

5.  Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.

Authors:  Desiree Jones; Elisabeth G Vichaya; Xin Shelley Wang; Mary H Sailors; Charles S Cleeland; Jeffrey S Wefel
Journal:  Cancer       Date:  2013-09-16       Impact factor: 6.860

6.  Evaluation of the accuracy of a pharmacokinetically-based patient-controlled analgesia system.

Authors:  H Hill; A Mackie; B Coda; R Schaffer; R Jacobson; C Benedetti
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

7.  Validation of the M. D. Anderson Symptom Inventory multiple myeloma module.

Authors:  Desiree Jones; Elisabeth G Vichaya; Xin Shelley Wang; Loretta A Williams; Nina D Shah; Sheeba K Thomas; Valen E Johnson; Richard E Champlin; Charles S Cleeland; Tito R Mendoza
Journal:  J Hematol Oncol       Date:  2013-02-05       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.